Diabetes Mellitus Clinical Trial
— ISMASOfficial title:
Inpatient Self Monitoring and Administration Study (ISMAS)
Verified date | December 2015 |
Source | Atlanta VA Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
ISMAS is designed to test the hypothesis that self management of insulin dependent diabetes mellitus by selected patients admitted for elective surgery is more efficacious than standard care with respect to overall glycemic control, attaining finger-stick blood sugars, and administering insulin.
Status | Active, not recruiting |
Enrollment | 1 |
Est. completion date | |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion criteria: 1. Male or female, age < 80 2. Most recent hemoglobin A1C within the past 6 months < 12% 3. Recent history of regular self-administered peripheral blood glucose checks as an outpatient 4. Recent history of insulin self-administration at least twice a day as an outpatient 5. Admitted for a hospitalization anticipated to last at least 3 days 6. Mini Mental Status Examination (MMSE) = 25 at admission and the same or better post-operatively 7. All patients will be actively followed by the Endocrinology inpatient consultation team during the hospitalization. Exclusion criteria: 1. Currently receiving peritoneal or hemodialysis 2. Patients with unstable angina 3. History of myocardial infarction within 3 weeks prior to enrollment 4. Current admission due to or associated with altered mental status or encephalopathy 5. History of an episode of altered mental status or encephalopathy within the 4 weeks prior to enrollment 6. A confirmed diagnosis of dementia 7. Inability to self-adjust insulin 8. No recent history of ability to perform regular peripheral blood glucose checks 9. Frequency of hypoglycemia (< 60 mg/dL) > twice/week by history 10. Inability to eat without assistance 11. Study objectives will not be pursued in patients during stays in any intensive care unit. |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Country | Name | City | State |
---|---|---|---|
United States | Atlanta VA Medical Center | Decatur | Georgia |
Lead Sponsor | Collaborator |
---|---|
Atlanta VA Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | number of blood glucose measurements obtained/number of blood glucose measurements ordered | patients will be followed for the duration of hospital stay, an expected average of 5 days | Yes | |
Primary | number of insulin doses administered/number of insulin doses prescribed | patients will be followed for the duration of hospital stay, an expected average of 5 days | Yes | |
Primary | average blood glucose | patients will be followed for the duration of hospital stay, an expected average of 5 days | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |